CBAY
CymaBay Therapeutics Inc.
18.20
USD
This page is just a preview of the data found in TrendSpider’s full version
CymaBay Therapeutics Inc. stock is up 10.98% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 08 Nov 18:47 | 19 Jan, 2024 | 15.00 | 463 | ||
| 09 Nov 18:10 | 17 Nov, 2023 | 14.00 | 111 | ||
| 09 Nov 19:25 | 19 Jan, 2024 | 17.00 | 621 | ||
| 09 Nov 19:26 | 19 Jan, 2024 | 17.00 | 621 | ||
| 09 Nov 19:42 | 19 Jan, 2024 | 16.00 | 71 | ||
| 10 Nov 15:38 | 17 Nov, 2023 | 14.00 | 2525 | ||
| 17 Nov 17:42 | 19 Jan, 2024 | 17.00 | 1366 | ||
| 20 Nov 19:21 | 19 Apr, 2024 | 15.00 | 56 | ||
| 21 Nov 15:30 | 19 Jan, 2024 | 19.00 | 0 | ||
| 27 Nov 15:57 | 19 Apr, 2024 | 22.00 | 18 |
CymaBay Therapeutics, Inc. focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics.
